CA3032004A1 - Methods for treating ulcerative colitis - Google Patents

Methods for treating ulcerative colitis Download PDF

Info

Publication number
CA3032004A1
CA3032004A1 CA3032004A CA3032004A CA3032004A1 CA 3032004 A1 CA3032004 A1 CA 3032004A1 CA 3032004 A CA3032004 A CA 3032004A CA 3032004 A CA3032004 A CA 3032004A CA 3032004 A1 CA3032004 A1 CA 3032004A1
Authority
CA
Canada
Prior art keywords
subject
treatment regimen
weeks
steroid
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3032004A
Other languages
English (en)
French (fr)
Inventor
Thomas Julius Borody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finch Therapeutics Holdings LLC
Original Assignee
Crestovo Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crestovo Holdings LLC filed Critical Crestovo Holdings LLC
Publication of CA3032004A1 publication Critical patent/CA3032004A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3032004A 2016-08-03 2017-08-02 Methods for treating ulcerative colitis Pending CA3032004A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662370508P 2016-08-03 2016-08-03
US62/370,508 2016-08-03
US15/360,703 US20180036352A1 (en) 2016-08-03 2016-11-23 Methods for treating ulcerative colitis
US15/360,703 2016-11-23
PCT/US2017/045092 WO2018026913A1 (en) 2016-08-03 2017-08-02 Methods for treating ulcerative colitis

Publications (1)

Publication Number Publication Date
CA3032004A1 true CA3032004A1 (en) 2018-02-08

Family

ID=61071386

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3032004A Pending CA3032004A1 (en) 2016-08-03 2017-08-02 Methods for treating ulcerative colitis

Country Status (7)

Country Link
US (5) US20180036352A1 (enExample)
EP (1) EP3493822A1 (enExample)
JP (2) JP7737219B2 (enExample)
CN (1) CN109803667A (enExample)
AU (1) AU2017306303B2 (enExample)
CA (1) CA3032004A1 (enExample)
WO (1) WO2018026913A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3045383B1 (fr) 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
US20180036352A1 (en) * 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
EP3518946A4 (en) 2016-09-27 2020-09-09 Board of Regents, The University of Texas System METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
CA3211208A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
CN111328284A (zh) 2017-08-07 2020-06-23 芬奇治疗公司 用于维持和恢复健康的肠道屏障的组合物和方法
KR102118203B1 (ko) * 2018-03-06 2020-06-02 주식회사 엠디헬스케어 코프로코커스 속 세균 유래 나노소포 및 이의 용도
FR3078627B1 (fr) * 2018-03-09 2020-11-13 Maat Pharma Procedure de collecte de selles et procede de preparation d'un echantillon pour transplantation de microbiote fecal
EP3597202A1 (en) * 2018-07-20 2020-01-22 Maat Pharma Fecal microbiota composition, for use in reducing treatment-induced inflammation
AU2019351017A1 (en) * 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
CN109394795A (zh) * 2018-10-23 2019-03-01 上海市第十人民医院 一种肠菌胶囊制备方法及肠菌胶囊
US20220080001A1 (en) * 2019-01-16 2022-03-17 Board Of Regents, The University Of Texas System Methods and compositions for treating immune checkpoint inhibitor associated colitis
CN115944654A (zh) 2019-07-19 2023-04-11 芬奇治疗控股有限责任公司 用于治疗胃肠道病症的方法及产品
US20230087012A1 (en) * 2020-02-14 2023-03-23 Cornell University Transferable microbiota for the treatment of ulcerative colitis
US20220120746A1 (en) * 2020-03-18 2022-04-21 Sabine Hazan Methods of Determining Susceptibility to COVID-19 Infection
US11744866B2 (en) * 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
CA3183811A1 (en) * 2020-06-29 2022-01-06 Marla C. DUBINSKY Systems and methods for evaluating a subject for inflammatory bowel disease management
CN111888381A (zh) * 2020-09-18 2020-11-06 广西细微生物科技有限责任公司 一种肠道微生物移植工艺
MX2023007621A (es) * 2020-12-23 2023-09-21 Maat Pharma Metodo para expandir una comunidad compleja de microorganismos.
CN113509494A (zh) * 2021-09-06 2021-10-19 南京医科大学 普氏菌在制备治疗胆汁淤积性疾病的药物中的应用
CN114246886B (zh) * 2021-12-24 2023-05-30 山西大学 规则粪球菌在制备预防和治疗急性结肠炎的制剂中的应用
CN115478031B (zh) * 2022-09-28 2025-04-18 中国科学院深圳先进技术研究院 防治炎症性肠病的胆汁酸代谢菌及其应用
KR20240114298A (ko) * 2023-01-12 2024-07-23 에스엔제이 파마 인크 감염 저항성 장내 균주 및 그 용도
CN119868571B (zh) * 2025-01-23 2025-11-21 浙江大学 扭链瘤胃球菌及其修饰菌在制备治疗溃疡性结肠炎的产品中的应用

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828E (fr) 1901-08-19 1904-06-30 Louis Emile Albert Durand Machine agricole dénommée gratteuse-bineuse-sulfateuse, destinée à travailler et sulfater simultanément les vignes ou tous végétaux plantés en rang
FR1275E (fr) 1902-02-21 1903-07-01 Buil Francois Sebastien Joseph Système de fixation des poignées de vélocipèdes
FR2427E (fr) 1903-08-19 1904-04-07 Paul Steinmetz Carburateur doseur, pour moteurs à explosion
FR5528E (fr) 1905-03-16 1906-05-02 Farcot Freres Et Cie Soc Perfectionnements aux turbines à vapeur ou à gaz
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
FR1275M (fr) 1961-05-06 1962-05-02 Rene Roger Médicament a base de colibacilles vivants.
NL294835A (enExample) 1962-07-19 1900-01-01
FR2828M (fr) 1963-03-01 1964-11-02 Lucien Nouvel Médicament renfermant des colibacilles antibiorésistants.
FR5528M (enExample) 1965-10-01 1967-11-13
GB1271674A (en) 1968-07-09 1972-04-26 Nisshin Flour Milling Co Process and preparation for treating diarrhoea in pigs
SE371209B (enExample) 1969-10-13 1974-11-11 Cernelle Ab
DE2134179A1 (de) 1971-07-09 1973-01-25 Rolf Dr Schuler Bifidobakterien enthaltendes praeparat und verfahren zur herstellung desselben
FR2244464A1 (en) 1973-06-26 1975-04-18 Serozym Laboratoires Yeast, lacto- and colibacillus based compsns - used to modify intestinal flora, treat colitis and digestive disorders, etc.
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4335107A (en) 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4309782A (en) 1980-09-11 1982-01-12 Esteban Paulin Device for collecting fecal specimens
US4536409A (en) 1981-01-23 1985-08-20 American Can Company Oxygen scavenger
US4394377A (en) 1981-07-31 1983-07-19 Syntex (U.S.A.) Inc. Ruminant animal performance by co-administering choline and propionate enchancers
US4452779A (en) 1982-02-03 1984-06-05 Cockerill Vernon Composition and method of treating lactating mammals
FI840816A0 (fi) 1984-03-01 1984-03-01 Farmos Oy Bakteriepreparat
JPS615022A (ja) 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd 腸内細菌叢改善剤
US4892731A (en) 1986-12-11 1990-01-09 Tadashi Arai Biological intestinal antiseptics
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
US4948734A (en) 1987-08-12 1990-08-14 Mycogen Corporation Novel isolates of bacillus thuringiensis having activity against nematodes
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5266315A (en) 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
JP3047143B2 (ja) 1992-04-24 2000-05-29 堀井薬品工業株式会社 腸管洗浄液用組成物及び腸管洗浄液
JP3850891B2 (ja) 1994-03-01 2006-11-29 ゼリア新薬工業株式会社 緩下効果を有する組成物
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
JPH07242557A (ja) 1994-03-03 1995-09-19 Ss Pharmaceut Co Ltd 乳酸菌含有瀉下薬組成物
HU220190B (hu) 1994-05-26 2001-11-28 Bracco S.P.A. Humán eredetű Lactobacillus törzsek, ilyen törzseket tartalmazó gyógyászati készítmények és alkalmazásuk
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5800821A (en) 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5858356A (en) 1995-12-21 1999-01-12 Abbott Laboratories Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
WO1998013068A1 (fr) 1996-09-26 1998-04-02 Vladimir Borisovich Kuperman Medicament prophylactique 'trisan'
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
US7374753B1 (en) 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US6428783B1 (en) 1998-03-11 2002-08-06 Medtech Center, Inc. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men
US5902743A (en) 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
CA2331966A1 (en) 1998-05-06 1999-11-11 Keijiro Nakamura Microbial culture liquors containing microorganisms differing in characteristics and living in symbiosis and metabolites thereof, carriers and absorbents containing the active components of the culture liquors and utilization of the same
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
AT407008B (de) 1998-08-06 2000-11-27 Viernstein Helmut Dr Formulierungen mit probiotisch wirksamen mikroorganismen
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
PL347058A1 (en) 1998-09-17 2002-03-11 North American Vaccine Streptococcal c beta protein compositions
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
WO2000035465A2 (en) 1998-12-11 2000-06-22 Urex Biotech Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7763276B1 (en) 1999-02-26 2010-07-27 Shionogi & Co., Ltd. Chewable soft capsules having improved administration properties and process for producing the same
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
CA2416120A1 (en) 2000-07-17 2002-01-24 Svend Laulund Methods and formulations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7214370B2 (en) 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US6790453B2 (en) 2001-03-14 2004-09-14 Mccormick & Company, Inc. Encapsulation compositions and process for preparing the same
US7815956B2 (en) 2001-04-27 2010-10-19 Pepsico Use of erythritol and D-tagatose in diet or reduced-calorie beverages and food products
ATE474559T1 (de) 2001-06-01 2010-08-15 Pozen Inc Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
JPWO2003004003A1 (ja) 2001-07-05 2004-10-21 湧永製薬株式会社 ソフトカプセル剤
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
CN1646102B (zh) 2002-04-05 2012-08-15 欧洲凯尔蒂克公司 含有羟氢可待酮和烯丙羟吗啡酮的药物制剂
CA2391422A1 (en) 2002-07-12 2004-01-12 David William Molloy Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,...
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
RU2006108554A (ru) 2003-08-18 2007-09-27 Дзе Байо Бэлэнс Корпорейшн (Us) Устойчивая жидкая пробиотическая композиция, ее получение и применения
US20060177424A1 (en) 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7759105B2 (en) 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8016816B2 (en) 2003-09-09 2011-09-13 Convatec Technologies Inc. Fecal management appliance and method and apparatus for introducing same
US7541091B2 (en) 2004-05-18 2009-06-02 M & G Usa Corporation Compartmentalized resin pellets for oxygen scavenging
EP1800688A1 (en) 2004-08-05 2007-06-27 Anidral S.R.L. Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
PL1673100T3 (pl) 2004-08-05 2008-01-31 Anidral Srl Szczepy bakterii Bifidobacterium wytwarzające kwas foliowy, preparaty i ich zastosowanie
US20060076536A1 (en) 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
WO2006127355A2 (en) 2005-05-20 2006-11-30 Dow Global Technologies Inc. Oral drug compliance monitoring using radio frequency identification tags
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
TWI362949B (en) 2005-09-13 2012-05-01 Bion Tech Inc Intestines dissolving nature is able to bear the hydrochloric acid in gastric juice and wrap up the benefit covered and grow the fungus of makes up
ATE489079T1 (de) 2005-12-29 2010-12-15 Osmotica Kereskedelmi Es Szolgaltata Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
JP5006567B2 (ja) 2006-04-14 2012-08-22 花王株式会社 口腔用固形製剤
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
JP2008106066A (ja) 2006-09-25 2008-05-08 Tashiro Yasuaki サポニン及び生菌を含有する組成物
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
CA2679480C (en) 2007-03-01 2016-10-18 Probi Ab Use of lactobacillus plantarum for increasing bacterial diversity
US8557233B2 (en) 2007-03-28 2013-10-15 Alimentary Heath Limited Probiotic bifidobacterium strains
KR20090127180A (ko) 2007-03-28 2009-12-09 앨러멘터리 헬스 리미티드 프로바이오틱 비피도박테리움 스트레인
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20100184785A1 (en) 2007-06-06 2010-07-22 Basf Se Pharmaceutical formulation for the production of chewable tablets and lozenges
ES2639130T3 (es) 2007-06-06 2017-10-25 Basf Se Formulación farmacéutica para la fabricación de comprimidos de rápida desintegración
EP2264042B1 (en) 2007-07-27 2012-07-18 Cargill, Incorporated Micronization of polyols
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
EP2183318B1 (en) 2007-08-31 2012-03-07 Invista Technologies S.A R.L. Oxygen scavenging plastic compositions
EP2196221A4 (en) 2007-09-27 2011-12-28 Mitsubishi Tanabe Pharma Corp QUICKLY CRUMPING SOLID PREPARATION
WO2009043844A2 (en) 2007-10-01 2009-04-09 Laboratorios Lesvi, S.L. Orodispersible tablets
CA2702935A1 (en) 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
ES2431572T3 (es) 2007-10-20 2013-11-27 Université de Liège Especies bifidobacterianas
EP2211879B1 (en) 2007-10-26 2014-05-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
JP5258268B2 (ja) 2007-11-19 2013-08-07 フロイント産業株式会社 球形粒の製造方法
US9314454B2 (en) 2007-12-28 2016-04-19 Sawai Pharmaceutical Co., Ltd. Oral cavity disintegrating tablet and method of producing the same
HRP20240317T1 (hr) 2008-10-02 2024-06-07 Salix Pharmaceuticals, Ltd. Liječenje hepatičke encefalopatije uporabom rifaksimina
US20100178413A1 (en) 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
US20100255231A1 (en) 2009-04-01 2010-10-07 Multisorb Technologies, Inc. Oxygen scavenging films
US9574169B2 (en) 2009-04-30 2017-02-21 Intrexon Actobiotics Nv Cryoprotectants for freeze drying of lactic acid bacteria
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
US20120064133A1 (en) 2009-05-28 2012-03-15 Ishwar Chauhan Multiparticulate Controlled-Release Selective Serotonin Reuptake Inhibitor Formulations
CN201441672U (zh) 2009-07-14 2010-04-28 赵伟华 一次性灌肠装置
US20110045222A1 (en) 2009-08-19 2011-02-24 Eastman Chemical Company Oxygen-scavenging polymer blends suitable for use in packaging
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
WO2011046616A2 (en) 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
US20110218216A1 (en) 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
EP3564357B1 (en) 2010-02-01 2022-04-06 Rebiotix, Inc. Bacteriotherapy for clostridium difficile colitis
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
CA2792647A1 (en) 2010-03-10 2011-09-15 Nogra Pharma Limited Compositions for colon lavage and methods of making and using same
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
BR112013002667B1 (pt) 2010-08-04 2020-02-04 Thomas Julius Borody composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las
KR20140033309A (ko) 2010-10-04 2014-03-18 브리티쉬 콜롬비아 캔써 에이전시 브랜치 위장 암을 진단하기 위해 위장의 샘플에서의 푸소박테리움의 검출
PL3072524T3 (pl) 2010-10-07 2018-06-29 California Institute Of Technology Probiotyczne terapie dla autyzmu
US20150374761A1 (en) 2011-03-09 2015-12-31 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
BR112013022927A2 (pt) * 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
WO2014152484A1 (en) * 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
CN103857402A (zh) 2011-10-11 2014-06-11 阿基姆医药公司 包括厌氧培养的人类肠道微生物群的组合物
FI3569690T3 (fi) 2011-12-01 2024-11-18 Univ Tokyo Ihmisperäisiä bakteereja, jotka saavat aikaan regulatoristen T-solujen proliferaatiota tai kerääntymistä
US9176026B2 (en) 2011-12-15 2015-11-03 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
CA2872149C (en) 2012-05-02 2019-03-19 Charles River Laboratories, Inc. Viability staining method
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2890808A4 (en) 2012-08-29 2016-09-28 California Inst Of Techn DIAGNOSIS AND TREATMENT OF AUTISTICAL DISEASES
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA2896795A1 (en) * 2012-11-26 2014-05-30 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
CA2899926C (en) 2013-02-04 2025-11-18 Seres Therapeutics Inc Compositions for populating a gastrointestinal tract
EP2968187A4 (en) 2013-03-14 2016-08-17 Therabiome Llc TARGETED GASTROINTESTINAL RELEASE OF PROBIOTIC ORGANISMS AND / OR THERAPEUTICS
AU2014262125B2 (en) 2013-04-30 2020-02-13 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
ES2673581T3 (es) 2013-06-05 2018-06-22 Rebiotix, Inc. Terapia de restauración de microbiota (TRM), compuestos y métodos de fabricación
WO2015006355A2 (en) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
AU2014331610B2 (en) 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof
EP3074027B1 (en) 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2016183577A1 (en) 2015-05-14 2016-11-17 Crestovo Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
BR112017024777A2 (pt) 2015-05-22 2018-08-07 Univ Arizona State uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados?
JP2018535254A (ja) 2015-10-26 2018-11-29 クレストヴォ・ホールディングス・エルエルシー 便微生物叢関連療法のための組成物及び方法
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis

Also Published As

Publication number Publication date
US20180125899A1 (en) 2018-05-10
JP7737219B2 (ja) 2025-09-10
US20200113949A1 (en) 2020-04-16
US20210330717A1 (en) 2021-10-28
US20190175665A1 (en) 2019-06-13
AU2017306303B2 (en) 2025-01-02
CN109803667A (zh) 2019-05-24
US20180036352A1 (en) 2018-02-08
JP2019525944A (ja) 2019-09-12
US10561690B2 (en) 2020-02-18
WO2018026913A1 (en) 2018-02-08
US12390496B2 (en) 2025-08-19
US10195235B2 (en) 2019-02-05
US11071759B2 (en) 2021-07-27
EP3493822A1 (en) 2019-06-12
JP2023010890A (ja) 2023-01-20
AU2017306303A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
US12390496B2 (en) Methods for treating ulcerative colitis
JP7273082B2 (ja) 自閉症スペクトラム障害および関連する症候を治療するための方法
US20210121503A1 (en) Fecal microbiota transplantation for treating ulcerative colitis
AU2020346061A1 (en) Compositions and methods for treating Autism Spectrum Disorder
US20210275603A1 (en) Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders
US20200046773A1 (en) Compositions and Method for Treating Primary Sclerosing Cholangitis and Related Disorders
US20210260136A1 (en) Compositions and Methods for Treating Multiple Sclerosis and Related Disorders
US20180099011A1 (en) Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders
US20200188449A1 (en) Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
US20240173360A1 (en) Compositions and methods for treating epilepsy and related disorders
US20200197449A1 (en) Compositions and Methods for Treating Alopecia and Related Disorders
US20180099013A1 (en) Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
US11040073B2 (en) Compositions and methods for treating diverticulitis and related disorders
HK40009325A (en) Methods for treating ulcerative colitis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220727

EEER Examination request

Effective date: 20220727

EEER Examination request

Effective date: 20220727

EEER Examination request

Effective date: 20220727